Your most challenging business questions require a customized solution. DeciBio Consulting provides tailored life science consulting services from industry veterans who have relevant clinical, research, and industry work experience. Partner with our seasoned experts to discover new market opportunities, evaluate how your products fit with customer needs, assess the impact of company initiatives, and understand market events and how they affect your company's bottom line and future growth.Read More
2/3 of Fortune & Global 500 research tools and clinical diagnostics companies trust DeciBio for intelligence and strategic guidance
100% of our cases focus on clinical diagnostics, research tools and health technology markets
70% of our consulting projects involve a global research perspective
More than 50% of our team has an advanced degree in a life science field
25% of our projects are supported by insights generated by big data analytics
Nobody has the combination of technical expertise, market insight, and strategic guidance that DeciBio possesses. Their work is thorough and data-driven, and they understand how their findings have a practical application to my business unit.Senior Director, Product Management, Oncology
As our company defines its expansion and detailed business planning, DeciBio has helped us understand the strength of the company brand with top global pharmaceutical companies. DeciBio is an exceptional partner to organizations interested in optimizing their position in the biotechnology and clinical research market space.Managing Director and Chief Business Officer
DeciBio is simply the top life science market research / consultancy in the industry based on their depth of expertise, their laser focus on our industry, and their commitment to top-notch client service.Vice President, Strategic Marketing
In our last blog post, Andrew covered how immuno-oncology is driving the development and utilization of digital pathology and multiplex spatial tissue analysis. In his blog, Andrew included all plex levels, but...
We’ve noticed a trend in the oncology biomarker this year. Both anecdotally, through our observations and discussions at AGBT and AACR and with our network of industry KOLs, and analytically, based on...
Since we last reported on the rise of tumor mutational burden (TMB) in immuno-oncology (I/O) a year ago, there have been numerous material developments of this biomarker in the I/O space. Just...